CLAIM AMENDMENTS

1. (Currently Amended) A compound of formulae



IA

~~or~~



IB

wherein

R^1 and R^2 are each independently selected from the group

hydrogen, lower alkyl,$-(CH_2)_nNR^5R^{5'}$ and $-(CH_2)_{n+1}OH$, with the proviso that at least one of R^1 and R^2 are $-(CH_2)_nNR^5R^{5'}$;

R^5 and $R^{5'}$ are each independently hydrogen or lower alkyl;

R^3 and R^4 are each independently selected from the group

hydrogen, lower alkyl, lower alkoxy, halogen, trifluoromethyl and hydroxy;

Ar is selected from the group phenyl and thiophenyl;

The dotted line is ~~selected from the group two hydrogens not forming~~ a bridge, and $-CH_2$-CHR'-, wherein R' is selected from the group

lower alkyl and hydrogen; and

n is 0, 1 or 2;

or a pharmaceutically acceptable acid addition salt thereof, with the proviso that when Ar is unsubstituted phenyl and R^2 is H, R^1 is not 2-amino.

2. Cancelled.

3. Cancelled.

4. (Currently Amended) A compound of formula



IA-2

wherein

R^1 and R^2 are each independently selected from the group hydrogen, lower alkyl, $-(CH_2)_nNR^5R^{5'}$ and $-(CH_2)_{n+1}OH$, with the proviso that at least one of R^1 and R^2 are $-(CH_2)_nNR^5R^{5'}$;

R^5 and $R^{5'}$ are each independently hydrogen or lower alkyl;

R^3 and R^4 are each independently selected from the group hydrogen, lower alkyl, lower alkoxy, halogen, trifluoromethyl and hydroxy; and

R' is selected from the group lower alkyl and hydrogen;

or a pharmaceutically acceptable acid addition salt thereof.

5. (Original) A compound of formula IA-2 according to claim 4, wherein R' is hydrogen.

6. (Currently Amended) A compound of formula IA-2 according to claim 5, selected from the group

2-(3,4-dihydro-naphthalen-2-yl)-pyridin-4-yl-amine,

2-(3,4-dihydro-naphthalen-2-yl)-6-methyl-pyridin-4-yl-amine,

[4-amino-6-(3,4-dihydro-naphthalen-2-yl)-pyridin-2-yl]-methanol,

2-(3,4-dihydro-naphthalen-2-yl)-5-methyl-pyridin-4-yl-amine,

2-(3,4-dihydro-naphthalen-2-yl)-6-ethyl-pyridin-4-yl-amine,

~~2-(3,4-dihydro-naphthalen-2-yl)-pyridin-4-yl]-methyl-amine,~~

2-(3,4-dihydro-naphthalen-2-yl)-pyridin-4-yl-methyl-amine,

~~C-[6-(3,4-dihydro-naphthalen-2-yl)-pyridin-2-yl]-methylamine~~,

[6-(3,4-dihydro-naphthalen-2-yl)-pyridin-2-yl]-methylamine,

2-(7-chloro-3,4-dihydro-naphthalen-2-yl)-pyridin-4-yl-amine,

2-(5,7-dimethyl-3,4-dihydro-naphthalen-2-yl)-pyridin-4-yl-amine,

2-(7-chloro-3,4-dihydro-naphthalen-2-yl)-6-ethyl-pyridin-4-yl-amine,

2-(7-chloro-3,4-dihydro-naphthalen-2-yl)-6-methyl-pyridin-4-yl-amine and

2-(7-chloro-3,4-dihydro-naphthalen-2-yl)-5-methyl-pyridin-4-yl-amine.

7. (Original) A compound of formula IA-2 according to claim 4, wherein R' is methyl.

8. (Original) A compound of formula IA-2 according to claim 7, selected from the group

rac.-2-(4-methyl-3,4-dihydro-naphthalen-2-yl)-pyridin-4-yl-amine,

rac.-2-methyl-6-(4-methyl-3,4-dihydro-naphthalen-2-yl)-pyridin-4-yl-amine and

rac.-5-methyl-2-(4-methyl-3,4-dihydro-naphthalen-2-yl)-pyridin-4-yl-amine.

9. (Currently Amended) A compound of formula



IA-4

wherein

R^1 and R^2 are each independently selected from the group hydrogen, lower alkyl, $-(CH_2)_nNR^5R^{5'}$ and $-(CH_2)_{n+1}OH$, with the proviso that at least one of R^1 and R^2 are $-(CH_2)_nNR^5R^{5'}$;

R^5 and $R^{5'}$ are each independently hydrogen or lower alkyl; and

R^3 and R^4 are each independently selected from the group hydrogen, lower alkyl, lower alkoxy, halogen, trifluoromethyl and hydroxy;

R' is selected from the group lower alkyl and hydrogen; and

n is 0, 1 or 2;

or a pharmaceutically acceptable acid addition salt thereof.

10. (Original) A compound of formula IA-4 according to claim 9, wherein R' is hydrogen.

11. (Original) A compound of formula IA-4 according to claim 10, selected from the group

2-(6,7-dihydro-benzo[b]thiophen-5-yl)-pyridin-4-yl-amine and 2-(6,7-dihydro-benzo[b]thiophen-5-yl)-5-methyl-pyridin-4-yl-amine.

12. Cancelled.

13. Cancelled.

14. (Currently Amended) A compound of formula IA ~~or IB~~ according to claim 1, wherein one of R^1 or R^2 is ~~amino~~ $\underline{NH_2}$.

15. (Original) A pharmaceutical composition comprising a compound of formula IA



IA

wherein

R^1 and R^2 are each independently selected from the group

hydrogen, lower alkyl,$-(CH_2)_nNR^5R^{5'}$ and $-(CH_2)_{n+1}OH$, with the proviso that at least one of R^1 and R^2 are $-(CH_2)_nNR^5R^{5'}$;

R^5 and $R^{5'}$ are each independently hydrogen or lower alkyl;

R^3 and R^4 are each independently selected from the group

hydrogen, lower alkyl, lower alkoxy, halogen, trifluoromethyl and hydroxy;

Ar is selected from the group phenyl and thiophenyl;

The dotted line is a bridge, and $-CH_2$-CHR'-, wherein R' is selected from the group

lower alkyl and hydrogen; and

n is 0, 1 or 2;

or a pharmaceutically acceptable acid addition salt thereof, with the proviso that when Ar is unsubstituted phenyl and R^2 is H, R^1 is not 2-amino;

~~or IB of claim 1,~~ combinations thereof or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

16. (Currently Amended) A method of ~~treatment~~ treating a ~~of~~ diseases ~~responsive to therapeutic indications for NMDA receptor subtype specific blockers, such as~~ selected from the group consisting of Alzheimer's disease, Parkinson's disease, Huntington's disease, ALS (amyotrophic lateral sclerosis), ~~and~~ neurodegeneration associated with bacterial or viral infections, ~~and, in addition~~, depression, and chronic or acute pain comprising administering to a patient a therapeutically effective amount of a compound of formula 1A ~~or IB according to claim 1,~~



IA

wherein

R^1 and R^2 are each independently selected from the group

hydrogen, lower alkyl,–$(CH_2)_nNR^5R^{5'}$ and –$(CH_2)_{n+1}OH$, with the proviso that at least one of R^1 and R^2 are –$(CH_2)_nNR^5R^{5'}$;

R^5 and $R^{5'}$ are each independently hydrogen or lower alkyl;

R^3 and R^4 are each independently selected from the group

hydrogen, lower alkyl, lower alkoxy, halogen, trifluoromethyl and hydroxy;

Ar is selected from the group phenyl and thiophenyl;

The dotted line is a bridge, and $-CH_2-CHR'-$, wherein R' is selected from the group lower alkyl and hydrogen; and

n is 0, 1 or 2;

or a pharmaceutically acceptable acid addition salt thereof, with the proviso that when Ar is unsubstituted phenyl and R^2 is H, R^1 is not 2-amino;

combinations thereof or a pharmaceutically acceptable salt thereof. ~~to a patient in need of such treatment.~~

17. Cancelled.

18. Cancelled.

19. Cancelled..

20. Cancelled.

21. (Currently Amended) A process for preparing a compound of formula[[e]] IA-2 comprising:

reacting a compound of formula



with a compound of formula



XIA

~~forming~~ to form a compound of formula



IA-2

wherein

R^1 and R^2 are each independently selected from the group hydrogen, lower alkyl, $-(CH_2)_nNR^5R^{5'}$ and $-(CH_2)_{n+1}OH$; wherein at least one of R^1 and R^2 is $-(CH_2)_nNR^5R^{5'}$;

R^5 and $R^{5'}$ are each independently hydrogen or lower alkyl; and

R^3 and R^4 are each independently selected from the group hydrogen, lower alkyl, lower alkoxy, halogen, trifluoromethyl and hydroxy; and

n is 0, 1 or 2.

22. Cancelled.